
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.


Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.
Learn from Drs. Buchheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.

Drs Nicola Hanania and Francesca Polverino explore the Many Faces of COPD: From Phenotypes to Endotypes.
An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.